THE NEGLECTED CONCERN OF FIRM SIZE IN PHARMACEUTICAL MERGERS.

The article focuses on Horizontal Merger Guidelines as per which the federal antitrust agencies have followed, and which the courts have accepted. It mentions Guidelines focus on ensuring that the combined entity does not have increased market power in specific drug markets, which includes ensuring that the buyer of any divested products can compete with the merged entity. It also mentions approach adequately addresses competitive concerns.